Tetanus Treatment Market Research Report Information, by type (Tetanus immune globulin (TIG), Tetanus toxoid (TT), Tetanus-diphtheria (Td), Diphtheria toxoid and acellular pertussis vaccine (DTaP)), by end user (Hospital, Clinics, Ambulatory centers, Research laboratory and others) - Forecast to 2030

Global Tetanus Treatment Market Overview

The tetanus treatment market is projected to reach USD 0.46 Billion by 2030 at 6.3% CAGR during the forecast period 2022-2030.

Tetanus is an infection that is a bacterial infection caused by Clostridium tetani. The bacteria create a poison (toxin) that causes painful muscular contractions when they enter the body. Tetanus is unique among vaccine-preventable diseases in that it does not transfer from one person to another. The bacteria can be found in various things like in soil, dust, and manure, and can enter the body through skin breaks, such as cuts or puncture wounds created by contaminated things. In the United States, tetanus is infrequent, with an average of 29 cases reported each year from 1996 to 2009.

Roche’s Multiple Sclerosis newcomer, Ocrevus, obtained FDA approval last March with a warning on immunization; now, clinical data compiled by researchers shows that it can interfere with the effectiveness of certain vaccines. In a phase 3b study funded by Roche, scientists examined immune responses to tetanus, seasonal flu, and pneumococcal vaccines as well as neoantigen keyhole limpet hemocyanin in over 100 MS patients who were either on or not on Ocrevus. It happened that patients under ocrelizumab had lower vaccine-induced immunity across the board. The percentage of treated subjects whose antibody titers for tetanus reached protective levels was 24% versus 55% in those without Ocrevus. For seroprotective titers against five influenza strains (ranging from 75% to 97%) and (55.6% -80%), respectively

On January 15th, 2024, the Ministry of Public Health launched an annual vaccination campaign against tetanus, diphtheria, and whooping cough (Tdap), which will be targeting private schools while other public schools are included since January 28th through collaboration with the Ministry of Education and Higher Education and Primary Health Care Corporation. This year, the campaign is meant to be aimed at vaccinating grade ten students in independent, private, and governmental schools within Qatar. “Vaccination campaign against Tetanus, Diphtheria and Pertussis annually being implemented aims at boosting boys’ girls’ students’ immunity towards these three diseases,” emphasized Dr Hamad Al-Rumaihi – Director of Health Protection & Communicable Diseases Control Department at MoPH.

With support from Gavi Vaccine Alliance partners, including WHO and UNICEF, amongst others, the Government of Nepal today launched a new vaccine campaign introducing Typhoid Conjugate Vaccine (TCV) into the routine immunization programme across the country. The objective of the three-week campaign is to reach all children from 15 months to 15 years so as to ensure the faster achievement of broader protection from typhoid, increase the impact of vaccine introduction, and counteract growing antimicrobial resistance. Over 50,000 immunization sites have been established throughout urban and rural communities in Nepal, including schools. Following this campaign, TCV will be added to the routine immunization schedule for administration to children at 15 months.

Tetanus treatment is a slowly increasing market. The Tetanus Treatment Market Share is expected to grow and be treated by various vaccines. Tetanus vaccines include Diphtheria, Tetanus, and Pertussis (DTaP); Monovalent Tetanus Toxoid (TT); Tetanus, Diphtheria, And Pertussis (Tdap); Diphtheria and Tetanus (DT); Diphtheria and Tetanus (DT); and more. The pediatric vaccines DTaP and DT are given to children under the age of seven, whereas Tdap and Td are given to children aged seven and up, where the lowercase letters 'd' and 'p' represent the lesser strengths of diphtheria and pertussis vaccines.

COVID Analysis

COVID-19, a novel coronavirus disease caused by the new coronavirus 2019-nCoV (now officially known as severe acute respiratory syndrome-related coronavirus), poses a pandemic threat to worldwide public health. Even though the COVID-19 outbreak began in Wuhan, China in December of 2019, the disease has now spread to over 100 nations, with over 100 000 confirmed cases and over 3,800 confirmed deaths worldwide. In addition, mandatory isolations/quarantines have impacted the lives of millions of people. If the COVID-19 outbreak is not adequately controlled, it might pose severe difficulties to global health systems and have far-reaching effects on the global economy. SARS virus (SARS-CoV), Middle East respiratory sickness (MERS-CoV), and the COVID-19 causal agent SARS-CoV-2 are all coronaviruses. SARS-CoV-2, like SARS-CoV and MERS-CoV, causes viral pneumonia in the lower respiratory system, but it can also impact the gastrointestinal system, heart, kidney, liver, and central nervous system, leading to multiple organ failure. Also, coronavirus can impact the Tetanus Treatment Market Value as various medications are going on for the virus which may not suit everyone and can lead to Tetanus Treatment Market Growth.

Tetanus Treatment Market Trends

Drivers

The most active, least priced, and best-tolerated vaccinations are the key drivers of Tetanus Treatment Market Analysis. The market is growing due to a rise in concern and understanding about immunization in emerging countries for disease control. The advancement of research and development processes increased awareness of illness prevention and treatment, and improved healthcare expenditure in developing nations will all contribute to positive demand for these vaccines. Currently, a big number of goods are undergoing clinical trials which will lead to greater market growth. The global market is likely to benefit from UNICEF, WHO, and other government activities to acquire tetanus vaccination for the prevention and treatment of tetanus.

Restraints

High Research & Development expenses, as well as tight restrictions in some countries, might stifle the tetanus treatment market share. Another issue that would harm market is the decrease in the number of reported cases of tetanus in industrialized countries.

Tetanus is an acute infectious disease caused by spores of the bacteria Clostridium tetani, according to the scope. These spores can be found in soil, animal and human intestinal tracts or excrement, skin surfaces, and rusted equipment like nails. Technological advancements and developments will give profitable opportunities for tetanus treatment market. Healthcare capital equipment spending, the installed base of various types of products, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market are all increasing as a result of technological advancements and will help in increasing the tetanus treatment market size.

Study Objectives

The report gives a complete analysis of the market structure, as well as forecasts for the major segments of the Tetanus treatment market for the next seven years. And also gives information on the elements that influence market growth.

The report gives historical and future revenue for market segments and major geographies and their countries and also gives a country-level market study in terms of current market size and prospects.

The report creates a competitive landscape for the market by providing an overview of important competitors and their strategic profiling in the market, extensively analyzing their core competencies, and drawing a competitive landscape.

Tetanus Treatment Market Segment Insights

The Global Tetanus Treatment Market is further bifurcated into various segments depending on various factors to help the market to grow as per the predicted CAGR growth by the end of the forecast period in 2027. The Global Tetanus Treatment Market is segmented based on the following:

Based on the type, the Global market has been segmented as follows:

• Inhalers


• Nebulizers

Based on the end-user, the Global market has been segmented as follows:

• Adults


• Kids

Tetanus Treatment Market Regional Classification

Asia-Pacific is the world's largest Tetanus treatment market. The market in Asia-Pacific is predicted to rise fast, reaching a peak by the end of the forecasted period. The second-largest market for Tetanus treatment in Europe. Due to rising cases of tetanus and diphtheria, as well as greater cost, coverage, and acceptance in this area, North America is likely to hold a significant market share in the worldwide. In the Middle East and Africa region are predicted to develop at the fastest rate. Furthermore, a greater emphasis on reducing the prevalence of disease and the availability of well-established healthcare infrastructure is supporting the overall regional market's rise to a substantial extent.

Americas

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Latin America

Europe

• Western Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • UK
  
  
  
  


• Rest of Western Europe


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• Australia


• South Korea

• Rest of Asia-Pacific

The Middle East & Africa

• Middle East


• Africa

Tetanus Treatment Market Competitive Landscape

Despite being fairly competitive and dominated by a few giant corporations, the industry in question is well-established in many areas and has a good track record of success. Its true potential in poor countries, on the other hand, has yet to be determined. People are getting more informed as a result of greater government initiatives, which are moving the market upward. The industry's growth is also projected to be boosted by strategic agreements and new product launches by major firms. The market for tetanus treatment is fragmented, competitive, and dominated by a few significant players. The major key players of the market are as follows:

• Accord Healthcare Inc.


• BB-NCIPD


• Biological E


• GlaxoSmithKline


• Massachusetts Biological Labs


• PT Bio Farma, Sanofi


• Serum Institute of India Pvt. Ltd.


• Bharat Pharmaceuticals


• Merck & Co. Inc.


• Shanha Biotechniques Pvt Ltd.


• Stablepharma


• Others

Recent Developments

In the United States, Merck & Co. Inc. and Sanofi cooperated to launch VAXELIS (diphtheria and tetanus treatment vaccine). The vaccine was authorized by the Food and Drug Administration during the historic forecast period.

Stablepharma established a partnership with BB-NCIPD (Bul Bio), a European vaccine manufacturer, to develop a thermally stable tetanus-diphtheria (Td) vaccine using the proprietary StablevaX formulation and apparatus.

Report Overview

The report on the Global Tetanus Treatment Market includes thorough primary research as well as rigorous qualitative and quantitative analysis by various industry experts and key opinion leaders to acquire a better understanding of the market and industry performance. The study depicts the current market landscape in detail, including historical and projected market size in terms of value and volume, technical advancements, macroeconomic considerations, and market controlling factors. The overall picture presented in the research depicts the current market scenario in great detail, including historical and predicted market sizes in terms of value and volume, technical advancements, macroeconomic factors, and market regulatory aspects. The report includes detailed information and plans for the industry's top major players. The study also provides an overview of the various market categories and geographies.